NCT06849037

Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo

and Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Who Will be Treated With Prophylactic Antibiotics Zinacef vs. Placebo

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 182 (estimated)
• Sponsor: Western Galilee Hospital-Nahariya · Other Government
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.

Detailed description

The relationship between meconium staining and chorioamnionitis, as well as neonatal sepsis, has been documented, yet the precise mechanisms remain unclear. Additionally, the correlation between prolonged labor and meconium staining was described in the past. In light of these findings, our randomized controlled double blind trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo. Additionally, we aimed to assess the distribution of pathogens in chorioamnionitic swab cultures relative to the antibiotic treatment

Conditions

• Meconium-stained Amniotic Fluid
• Chorioamnionitis

Interventions

Type	Name	Description
DRUG	zinacef tretment	prophylactic antibiotic treatment with zinacef
OTHER	Placebo	I.V SALINE 100 CC X3/d

Timeline

• Start date: 2025-02-18
• Primary completion: 2028-02-13
• Completion: 2029-02-13
• First posted: 2025-02-27
• Last updated: 2025-07-20

Locations

1 site across 1 country: Israel